Targeting HIF2 in clear cell renal cell carcinoma

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 81, Issue 1, 2016, Pages 113-121

  Cho, Hyejin ^a   Kaelin, William G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 2; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA ANTAGONIST; OXYGEN; PT 2385; PT 2399; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ARNTL; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CARCINOGENESIS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DIMERIZATION; DRUG TARGETING; GENE EDITING; GENE EXPRESSION; HUMAN; KIDNEY CARCINOMA; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TUMOR XENOGRAFT; ANIMAL; KIDNEY TUMOR; METABOLISM; RENAL CELL CARCINOMA;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 85020798998     PISSN: 00917451     EISSN: 19434456     Source Type: Book Series    
DOI: 10.1101/sqb.2016.81.030833     Document Type: Article

References (93)

1. Adam J, Hatipoglu E, O'Flaherty L, Ternette N, Sahgal N, Lockstone H, Baban D, Nye E, StampGW,Wolhuter K, et al. 2011. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: Roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20: 524-537
2. Albers J, Rajski M, Schonenberger D, Harlander S, Schraml P, von Teichman A, Georgiev S, Wild PJ, Moch H, Krek W, et al. 2013. Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice. EMBO Mol Med 5: 949-964
3. Baba M, Hirai S, Yamada-Okabe H, Hamada K, Tabuchi H, Kobayashi K, Kondo K, Yoshida M, Yamashita A, Kishida T, et al. 2003. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Oncogene 22: 2728-2738
4. Benjamin LE, Keshet E. 1997. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci 94: 8761-8766
5. Benjamin LE, Hemo I, Keshet E. 1998. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGFB and VEGF. Development 125: 1591-1598
6. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. 1999. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165
7. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D,Worrell RA, Moch H, Rubin MA, et al. 2009. Patterns of gene expression and copy-number alterations in von Hippel-Lindau disease-Associated and sporadic clear cell carcinoma of the kidney. Cancer Res 69: 4674-4681
8. Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD. 2002. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 62: 3014-3019
9. Biswas S, Troy H, Leek R, Chung YL, Li JL, Raval RR, Turley H, Gatter K, Pezzella F, Griffiths JR, et al. 2010. Effects of HIF-1α and HIF2α on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts. J Oncol 2010: 757908
10. -/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci 105: 16484-16489
11. Cancer Genome Atlas Research Network. 2013. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499: 43-49
12. Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, et al. 2016. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539: 112-117
13. Cho H, Du X, Rizzi JP, Liberzon E, Chakraborty AA, Gao W, Carvo I, Signoretti S, Bruick R, Josey JA, et al. 2016. Ontarget efficacy of a HIF2a antagonist in preclinical kidney cancer models. Nature 539: 107-111
14. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, et al. 2015. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373: 1814-1823
15. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, et al. 2016. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17: 917-927
16. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, et al. 2010. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360-363
17. Davidowitz E, Schoenfeld A, Burk R. 2001. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol 21: 865-874
18. -/- clear cell renal carcinoma cell proliferation: A possible mechanism coupling von Hippel-Lindau tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci 13: 1387-1392
19. Dondeti VR, Wubbenhorst B, Lal P, Gordan JD, D'Andrea K, Attiyeh EF, Simon MC, Nathanson KL. 2012. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res 72: 112-121
20. Duns G, Hofstra RM, Sietzema JG, Hollema H, van Duivenbode I, Kuik A, Giezen C, Jan O, Bergsma JJ, Bijnen H, et al. 2012. Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum Mutat 33: 1059-1062
21. Fisher R, Horswell S, Rowan A, Salm MP, de Bruin EC, Gulati S, McGranahan N, Stares M, Gerlinger M, Varela I, et al. 2014. Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome Biol 15: 433
22. Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, Lee S. 2007. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci 104: 13092-13097
23. Frew IJ, Thoma CR, Georgiev S, Minola A, Hitz M, Montani M, Moch H, KrekW. 2008. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 27: 1747-1757
24. Gassenmaier M, Chen D, Buchner A, Henkel L, Schiemann M, Mack B, Schendel DJ, ZimmermannW, Pohla H. 2013. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. Stem Cells 31: 1467-1476
25. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892
26. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, et al. 2014. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 46: 225-233
27. Gnarra J, Ward J, Porter F, Wagne J, Devor D, Grinberg A, Emmert-Buck M, Westphal H, Klausner R, Linehan W. 1997. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci 94: 9102-9107
28. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, et al. 2008. HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14: 435-446
29. Guo G, Gui Y, Gao S, Tang A, Hu X, Huang Y, Jia W, Li Z, He M, Sun L, et al. 2011. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 44: 17-19
30. Hainsworth JD, Spigel DR, Sosman JA, Burris HA III, Farley C, Cucullu H, Yost K, Hart LL, Sylvester L, Waterhouse DM, et al. 2007. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: A phase I/II trial. Clin Genitourin Cancer 5: 427-432
31. Hu C-J, Wang L-Y, Chodosh LA, Keith B, Simon MC. 2003. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2a in hypoxic gene regulation. Mol Cell Biol 23: 9361-9374
32. Iliopoulos O, Kibel A, Gray S, Kaelin WG. 1995. Tumor suppression by the human von Hippel-Lindau gene product. Nat Med 1: 822-826
33. Kaelin WG. 2002. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2: 673-682
34. Kaelin WG Jr. 2007. von Hippel-Lindau disease. Annu Rev Pathol 2: 145-173
35. KaelinWGJr. 2008. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873
36. Kaelin WG Jr, Ratcliffe PJ. 2008. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402
37. Kapitsinou PP, Liu Q, Unger TL, Rha J, Davidoff O, Keith B, Epstein JA, Moores SL, Erickson-Miller CL, Haase VH. 2010. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 116: 3039-3048
38. Keith B, Johnson RS, Simon MC. 2012. HIF1α and HIF2α: Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12: 9-22
39. KimWY, SafranM, Buckley MR, Ebert BL, Glickman J, Bosenberg M, Regan M, Kaelin WG Jr. 2006. Failure to prolyl hydroxylate hypoxia-inducible factor a phenocopies VHL inactivation in vivo. EMBO J 25: 4650-4662
40. Knebelmann B, Ananth S, Cohen H, Sukhatme V. 1998. Transforming growth factor a is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 58: 226-231
41. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG. 2002. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246
42. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. 2003. Inhibition of HIF2a is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1: 439-444
43. Koochekpour S, Jeffers M,Wang P, Gong C, Taylor G, Roessler L, Stearman R, Vasselli J, Stetler-Stevenson W, Kaelin WJ, et al. 1999. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 19: 5902-5912
44. Li L, Zhang L, Zhang X, Yan Q, Minamishima YA, Olumi AF, Mao M, Bartz S, Kaelin WG Jr. 2007. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol 27: 5381-5392
45. Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel R. 1998. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res 58: 4957-4962
46. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z. 1996. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149: 2089-2094
47. Maher E, Kaelin WG. 1997. von Hippel-Lindau disease. Medicine 76: 381-391
48. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, et al. 2002. HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1: 459-468
49. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. 2002. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1: 247-255
50. Merseburger AS, Hennenlotter J, Simon P, Kruck S, Koch E, Horstmann M, Kuehs U, Kufer R, Stenzl A, Kuczyk MA. 2005. Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Anticancer Res 25: 1901-1907
51. Micucci C, Matacchione G, Valli D, Orciari S, Catalano A. 2015. HIF2a is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma. Br J Cancer 113: 1178-1185
52. Montani M, Heinimann K, von Teichman A, Rudolph T, Perren A, Moch H. 2010. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: Further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Am J Surg Pathol 34: 806-815
53. Morris MR, Hughes DJ, Tian YM, Ricketts CJ, Lau KW, Gentle D, Shuib S, Serrano-Fernandez P, Lubinski J, Wiesener MS, et al. 2009. Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma. Anticancer Res 29: 4337-4343
54. Nakaigawa N, Yao M, Baba M, Kato S, Kishida T, Hattori K, Nagashima Y, Kubota Y. 2006. Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res 66: 3699-3705
55. Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, Reckamp K, Belperio JA, Strieter RM. 2006. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 5: 56
56. + myeloid derived suppressor cells. Mol Cancer 12: 17
57. Pause A, Lee S, Lonergan KM, Klausner RD. 1998. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci 95: 993-998
58. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P, et al. 2012. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 44: 751-759
59. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. 2003. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3: 347-361
60. Polite BN, Desai AA, Manchen B, Stadler WM. 2006. Combination therapy of imatinib mesylate and interferon-α demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: Results of a single-institution phase II trial. Clin Genitourin Cancer 4: 275-280
61. Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, Moore LE, Prokhortchouk E, Wu X, Kiemeney LA, Gaborieau V, et al. 2011. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet 43: 60-65
62. Ramp U, Jaquet K, Reinecke P, Schardt C, Friebe U, Nitsch T, Marx N, Gabbert HE, Gerharz CD. 1997. Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type. J Urol 157: 2345-2350
63. Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, Simon MC, Keith B, Haase VH. 2007. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 117: 1068-1077
64. Rankin EB, Rha J, Unger TL, Wu CH, Shutt HP, Johnson RS, Simon MC, Keith B, Haase VH. 2008. Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene 27: 5354-5358
65. Rankin EB, Rha J, Selak MA, Unger TL, Keith B, Liu Q, Haase VH. 2009. HIF-2 regulates hepatic lipid metabolism. Mol Cell Biol 29: 4527-4538
66. Raval RR, LauKW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. 2005. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-5686
67. Rogers JL, Bayeh L, Scheuermann TH, Longgood J, Key J, Naidoo J, Melito L, Shokri C, Frantz De, Bruick RK, et al. 2013. Development of inhibitors of the PAS-B domain of the HIF-2a transcription factor. J Med Chem 56: 1739-1747
68. Ryan CW, Vuky J, Chan JS, Chen Z, Beer TM, Nauman D. 2011. A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma. Invest New Drugs 29: 374-379
69. Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, et al. 2014. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med 3: 1485-1492
70. Scheuermann TH, Tomchick DR, Machius M, Guo Y, Bruick RK, Gardner KH. 2009. Artificial ligand binding within the HIF2a PAS-B domain of the HIF2 transcription factor. Proc Natl Acad Sci 106: 450-455
71. Scheuermann TH, Li Q, Ma HW, Key J, Zhang L, Chen R, Garcia JA, Naidoo J, Longgood J, Frantz De, et al. 2013. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol 9: 271-276
72. Schietke RE, Hackenbeck T, Tran M, Gunther R, Klanke B, Warnecke CL, Knaup KX, Shukla D, Rosenberger C, Koesters R, et al. 2012. Renal tubular HIF-2a expression requires VHL inactivation and causes fibrosis and cysts. PLoS One 7: e 31034
73. Schodel J, Bardella C, Sciesielski LK, Brown JM, Pugh CW, Buckle V, Tomlinson IP, Ratcliffe PJ, Mole DR. 2012. Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. Nat Genet 44: 420-425, S421-S 422
74. Semenza GL. 2011. Oxygen sensing, homeostasis, and disease. N Engl J Med 365: 537-547
75. Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, Signoretti S, Kaelin WG Jr. 2011. Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov 1: 222-235
76. Siegel RL, Miller KD, Jemal A. 2016. Cancer statistics, 2016. CA Cancer J Clin 66: 7-30
77. -/- renal cancer. Cancer Res 65: 5221-5230
78. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, KrekW. 2003. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425: 307-311
79. Struckmann K, Mertz K, Steu S, Storz M, Staller P, Krek W, Schraml P, Moch H. 2008. pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J Pathol 214: 464-471
80. Uhlman DL,Nguyen P,Manivel JC, Zhang G, HagenK, Fraley E, Aeppli D, Niehans GA. 1995. Epidermal growth factor receptor and transforming growth factor a expression in papillary and nonpapillary renal cell carcinoma: Correlation with metastatic behavior and prognosis. Clin Cancer Res 1: 913-920
81. Uniacke J, Holterman CE, Lachance G, Franovic A, Jacob MD, Fabian MR, Payette J, Holcik M, Pause A, Lee S. 2012. An oxygen-regulated switch in the protein synthesis machinery. Nature 486: 126-129
82. Vanharanta S, ShuW, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massague J. 2013. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med 19: 50-56
83. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, et al. 2011. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469: 539-542
84. Vuky J, Isacson C, Fotoohi M, dela Cruz J, Otero H, Picozzi V, Malpass T, Aboulafia D, Jacobs A. 2006. Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. Invest New Drugs 24: 85-88
85. Wallace EM, Rizzi JP, Han G,Wehn PM, Cao Z, Du X, Cheng T, Czerwinski RM, Dixon DD, Goggin BS, et al. 2016. A smallmolecule antagonist of HIF2a is efficacious in preclinical models of renal cell carcinoma. Cancer Res 76: 5491-5500
86. Walther M, Lubensky I, Venzon D, Zbar B, Linehan W. 1995. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: Clinical implications. J Urol 154: 2010-2014
87. Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, Li F, Tsang S, Wu K, Wu H, et al. 2012. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148: 886-895
88. Zagzag D, Krishnamachary B, Yee H, Okuyama H, Chiriboga L, Ali MA, Melamed J, Semenza GL. 2005. Stromal cell-derived factor-1α and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-offunction induces expression of a ligand and its receptor. Cancer Res 65: 6178-6188
89. Zatyka M, da Silva NF, Clifford SC, Morris MR,Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER. 2002. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62: 3803-3811
90. Zhang T, Niu X, Liao L, Cho EA, Yang H. 2013. The contributions of HIF-target genes to tumor growth in RCC. PLoS One 8: e 80544
91. Zhou L, Yang H. 2011. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR. PLoS One 6: e 23936
92. Zhuang Z, Bertheau P, Emmert-Buck MR, Liotta L, Gnarra J, Linehan WM, Lubensky IA. 1995. A microscopic dissection technique for archival DNA analysis of specific cell populations in lesions <1 mm in size. Am J Pathol 146: 620-625
93. -/- tumors. Mol Cancer Res 2: 89-95